Steve Schonfeld’s ANI Pharmaceuticals ANIP Stock Holding History

Steve Schonfeld’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.41M	Sell	41,217 -144,412	-78%	-$11.6M	0.01%	796
2026 Q1	$14.3M	Sell	185,629 -6,377	-3%	-$498K	0.1%	225
2025 Q4	$15.2M	Buy	192,006 +170,206	+781%	+$14.7M	0.07%	256
2025 Q3	$2M	Sell	21,800 -15,748	-42%	-$1.28M	0.01%	1032
2025 Q2	$2.45M	Sell	37,548 -37,444	-50%	-$2.44M	0.02%	872
2025 Q1	$5.02M	Buy	+74,992	New	+$4.48M	0.03%	521
2024 Q1	–	Sell	-3,831	Closed	-$211K	–	2045
2023 Q4	$211K	Sell	3,831 -27,969	-88%	-$1.54M	﹤0.01%	1522
2023 Q3	$1.85M	Sell	31,800 -18,200	-36%	-$1.05M	0.01%	853
2023 Q2	$2.69M	Buy	50,000 +20,250	+68%	+$898K	0.02%	662
2023 Q1	$1.18M	Sell	29,750 -10,096	-25%	-$426K	0.01%	885
2022 Q4	$1.6M	Buy	+39,846	New	+$1.5M	0.01%	917

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steve Schonfeld's ANIP Position: Q2 2026 in Review

Steve Schonfeld reduced its ANI Pharmaceuticals (ANIP) stake by 78% in Q2 2026, selling an estimated $11.6M and leaving 41,217 shares worth $3.41M. The position accounts for 0.01% of the portfolio, ranked #796.

Steve Schonfeld first reported a position in ANIP in Q4 2022 and has held it in 11 quarters since. The position peaked at $15.2M in Q4 2025. 305 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Steve Schonfeld held 41,217 shares of ANI Pharmaceuticals worth $3.41M as of Q2 2026.
Steve Schonfeld sold 144,412 ANI Pharmaceuticals shares in Q2 2026, an estimated $11.6M.
ANI Pharmaceuticals made up 0.01% of Steve Schonfeld's portfolio in Q2 2026, its #796 holding.
Steve Schonfeld first reported a position in ANI Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
Steve Schonfeld's ANI Pharmaceuticals position peaked at $15.2M in Q4 2025.
305 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.